<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371367</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals.</ArticleTitle><Pagination><StartPage>ofae527</StartPage><MedlinePgn>ofae527</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae527</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae527</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Current COVID-19 vaccines primarily target the Spike protein of defined virus variants, offering limited protection against emerging variants in immunocompetent individuals. Similarly, protective immunity following natural SARS-CoV-2 infection is variable and of short duration, raising concerns about immunocompromised individuals' vaccination strategies.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This prospective multicenter study examined 66 sera from 59 immunocompromised and 451 sera from 215 immunocompetent individuals from different pandemic periods. We establish and validate a live virus-based neutralization assay to determine the virus-inactivating potential against ancestral and current SARS-CoV-2 isolates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our virus-based neutralization assay demonstrated superior performance over surrogate neutralization assays. We found strong but transient immunity after complete vaccination schemes, with single doses providing minimum neutralization, regardless of vaccine type. Combining vaccination-induced immunity with SARS-CoV-2 infection before or after vaccination yielded higher neutralizing titers than vaccination or infection alone, consistent across both study groups. Additional doses after a full vaccination course restored neutralization levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Potentially protective SARS-CoV-2 neutralization is reliably induced in immunocompromised individuals by prior attenuation of immunosuppression. First-generation vaccines protect against various SARS-CoV-2 variants in immunocompetent individuals, with effective cross-neutralization demonstrated up to the Delta variant but largely absent for later Omicron variants. Continuous vaccine updates are necessary to address emerging SARS-CoV-2 variants.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9950-365X</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urda</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0007-4122-515X</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittelholzer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4353-3555</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otte</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0572-617X</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipfer</LastName><ForeName>Enja</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5870-6784</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuepeng</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0009-7923-2173</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lett</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7230-9264</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schebitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gemeinschaftspraxis Martinstrasse, Kinder- und Jugendmedizin, Olpe, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Roman-Ulrich</ForeName><Initials>RU</Initials><Identifier Source="ORCID">0000-0001-6910-0745</Identifier><AffiliationInfo><Affiliation>Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimkait</LastName><ForeName>Wilfried</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>KfH-Nierenzentrum, Heilig-Geist-Gesundheitszentrum, Köln-Longerich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimkait</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4945-6511</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunodeficiency</Keyword><Keyword MajorTopicYN="N">kidney transplant</Keyword><Keyword MajorTopicYN="N">live neutralization</Keyword><Keyword MajorTopicYN="N">transplant patient</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. All authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371367</ArticleId><ArticleId IdType="pmc">PMC11450466</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae527</ArticleId><ArticleId IdType="pii">ofae527</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO . WHO director-General's opening remarks at the media briefing—5 May 2023. Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing—5-may-2023. Accessed 20 Dec 2023.</Citation></Reference><Reference><Citation>Kohn  GC. Encyclopedia of plague and pestilence: from ancient times to the present. New York, USA: Infobase Publishing, 2007.</Citation></Reference><Reference><Citation>Marot  S, Malet  I, Leducq  V, et al.  Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun  2021; 12:844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870823</ArticleId><ArticleId IdType="pubmed">33558507</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyke  KE, Atmar  RL, Islas  CD, et al.  Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 omicron variant. Cell Rep Med  2022; 3:100679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212999</ArticleId><ArticleId IdType="pubmed">35798000</ArticleId></ArticleIdList></Reference><Reference><Citation>Campi  G, Bianconi  A. Periodic recurrent waves of COVID-19 epidemics and vaccination campaign. Chaos Solitons Fractals  2022; 160:112216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9114150</ArticleId><ArticleId IdType="pubmed">35601116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson  SAJ, Richter  A, Casey  A, et al.  Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol  2022; 8:veac050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384748</ArticleId><ArticleId IdType="pubmed">35996593</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield  J, Megill  C, Bell  SM, et al.  Nextstrain: real-time tracking of pathogen evolution. Bioinformatics  2018; 34:4121–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247931</ArticleId><ArticleId IdType="pubmed">29790939</ArticleId></ArticleIdList></Reference><Reference><Citation>Minskaia  E, Hertzig  T, Gorbalenya  AE, et al.  Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A  2006; 103:5108–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458802</ArticleId><ArticleId IdType="pubmed">16549795</ArticleId></ArticleIdList></Reference><Reference><Citation>Amicone  M, Borges  V, Alves  MJ, et al.  Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evol Med Public Health  2022; 10:142–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8996265</ArticleId><ArticleId IdType="pubmed">35419205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopsidas  I, Karagiannidou  S, Kostaki  EG, et al.  Global distribution, dispersal patterns, and trend of several omicron subvariants of SARS-CoV-2 across the globe. Trop Med Infect Dis  2022; 7:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9698960</ArticleId><ArticleId IdType="pubmed">36422924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty  C, Bhattacharya  M, Sharma  AR, Mallik  B. Omicron (B.1.1.529)—a new heavily mutated variant: mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol  2022; 219:980–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359758</ArticleId><ArticleId IdType="pubmed">35952818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao  Z, Zhou  J, Tian  M, et al.  Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. Nat Commun  2022; 13:4958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9399999</ArticleId><ArticleId IdType="pubmed">36002453</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey  WT, Carabelli  AM, Jackson  B, et al.  SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol  2021; 19:409–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang  F, Chen  L, Guo  W, et al.  Identifying COVID-19 severity-related SARS-CoV-2 mutation using a machine learning method. Life (Basel)  2022; 12:806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225528</ArticleId><ArticleId IdType="pubmed">35743837</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai  H, Chan  JF-W, Hu  B, et al.  Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 omicron. Nature  2022; 603:693–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35062016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura  T, Yamasoba  D, Oda  Y, et al.  Comparative pathogenicity of SARS-CoV-2 omicron subvariants including BA.1, BA.2, and BA.5. Commun Biol  2023; 6:772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10366110</ArticleId><ArticleId IdType="pubmed">37488344</ArticleId></ArticleIdList></Reference><Reference><Citation>Uusküla  A, Pisarev  H, Tisler  A, et al.  Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia. Sci Rep  2023; 13:20347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10663482</ArticleId><ArticleId IdType="pubmed">37989858</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh  HN, Chemaitelly  H, Ayoub  HH, et al.  Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. eBioMedicine  2023; 95:104734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10404859</ArticleId><ArticleId IdType="pubmed">37515986</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz  LL, Juhl  AK, Søgaard  OS, et al.  Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity. Commun Med (Lond)  2023; 3:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10124939</ArticleId><ArticleId IdType="pubmed">37095240</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier  DA, Ferreira  IATM, Kotagiri  P, et al.  Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature  2021; 596:417–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack  FP, Thomas  SJ, Kitchin  N, et al.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med  2020; 383:2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden  LR, El Sahly  HM, Essink  B, et al.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med  2021; 384:403–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Griessbach  A, Chammartin  F, Abela  IA, et al.  Antibody response after the third SARS-CoV-2 vaccine in solid organ transplant recipients and people living with HIV (COVERALL-2). Open Forum Infect Dis  2023; 10:ofad536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10655940</ArticleId><ArticleId IdType="pubmed">38023564</ArticleId></ArticleIdList></Reference><Reference><Citation>Speich  B, Chammartin  F, Abela  IA, et al.  Antibody response in immunocompromised patients after the administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine BNT162b2 or mRNA-1273: a randomized controlled trial. Clin Infect Dis  2022; 75:e585–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903480</ArticleId><ArticleId IdType="pubmed">35234868</ArticleId></ArticleIdList></Reference><Reference><Citation>Li  J, Ayada  I, Wang  Y, et al.  Factors associated with COVID-19 vaccine response in transplant recipients: a systematic review and meta-analysis. Transplantation  2022; 106:2068–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9521391</ArticleId><ArticleId IdType="pubmed">35761439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadban  SJ, Ahn  C, Axelrod  DA, et al.  KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation  2020; 104:S11–103.</Citation><ArticleIdList><ArticleId IdType="pubmed">32301874</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Arndt  L, Braun  J, Fauchere  F, et al.  SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. J Neurol Neurosurg Psychiatry  2022; 93:960–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380499</ArticleId><ArticleId IdType="pubmed">35835468</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrezenmeier  E, Rincon-Arevalo  H, Jens  A, et al.  Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients. JCI Insight  2022; 7:e157836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9090237</ArticleId><ArticleId IdType="pubmed">35349490</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams  DM, Hornsby  HR, Shehata  OM, et al.  Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy. iScience  2023; 26:107056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10246304</ArticleId><ArticleId IdType="pubmed">37346049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang  NY-L, Pang  AS-R, Chow  VT, Wang  D-Y. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res  2021; 8:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405719</ArticleId><ArticleId IdType="pubmed">34465396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner  KM, Yadav  R, Noble  EK, et al.  Anti–SARS-CoV-2 antibody levels associated with COVID-19 protection in outpatients tested for SARS-CoV-2, US flu vaccine effectiveness network, October 2021–June 2022. J Infect Dis  2024; 230:45–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11272097</ArticleId><ArticleId IdType="pubmed">39052724</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra  M, Tian  R, Zhang  C, et al.  Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep  2021; 11:3455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875990</ArticleId><ArticleId IdType="pubmed">33568776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu  H, Guan  F, Miller  H, Lei  J, Liu  C. The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development. Emerg Microbes Infect  2023; 12:e2164219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9980416</ArticleId><ArticleId IdType="pubmed">36583642</ArticleId></ArticleIdList></Reference><Reference><Citation>Jörrißen  P, Schütz  P, Weiand  M, et al.  Antibody response to SARS-CoV-2 membrane protein in patients of the acute and convalescent phase of COVID-19. Front Immunol  2021; 12:679841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371319</ArticleId><ArticleId IdType="pubmed">34421894</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans  JP, Zeng  C, Carlin  C, et al.  Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med  2022; 14:eabn8057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939766</ArticleId><ArticleId IdType="pubmed">35166573</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Saleh  H, Abo-Halawa  BY, Younes  S, et al.  Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. J Travel Med  2022; 29:taac130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9793397</ArticleId><ArticleId IdType="pubmed">36342115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates  TA, Leier  HC, Lyski  ZL, et al.  Age-Dependent neutralization of SARS-CoV-2 and P.1 variant by vaccine immune Serum samples. JAMA  2021; 326:868–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8295896</ArticleId><ArticleId IdType="pubmed">34287620</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastassopoulou  C, Antoni  D, Manoussopoulos  Y, et al.  Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: a mixed effects model across two vaccination periods. PLoS One  2022; 17:e0266958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9053797</ArticleId><ArticleId IdType="pubmed">35486622</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano  T, Sato  T, Kotaki  R, et al.  Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Nat Commun  2023; 14:1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10016167</ArticleId><ArticleId IdType="pubmed">36922492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu  J-D, Li  J-X, Liu  J, et al.  Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Lancet Infect Dis  2023; 23:1020–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">37216958</ArticleId></ArticleIdList></Reference><Reference><Citation>Breathnach  AS, Riley  PA, Cotter  MP, Houston  AC, Habibi  MS, Planche  TD. Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. J Infect  2021; 82:e11–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804382</ArticleId><ArticleId IdType="pubmed">33450303</ArticleId></ArticleIdList></Reference><Reference><Citation>Oran  DP, Topol  EJ. Prevalence of asymptomatic SARS-CoV-2 infection. Ann Intern Med  2020; 173:362–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281624</ArticleId><ArticleId IdType="pubmed">32491919</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrokwa  SK, Müller  SA, Méndez-Brito  A, Hanefeld  J, El Bcheraoui  C. Recurrent SARS-CoV-2 infections and their potential risk to public health—a systematic review. PLoS One  2021; 16:e0261221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659325</ArticleId><ArticleId IdType="pubmed">34882750</ArticleId></ArticleIdList></Reference><Reference><Citation>Azam  M, Sulistiana  R, Ratnawati  M, et al.  Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep  2020; 10:20692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691365</ArticleId><ArticleId IdType="pubmed">33244060</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli  M, Penfold  RS, Merino  J, et al.  Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis  2022; 22:43–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>